Tobira Therapeutics Inc. (NASDAQ:TBRA) shares rose 3.2% during mid-day trading on Tuesday . The company traded as high as $5.16 and last traded at $5.09, with a volume of 163,837 shares changing hands. The stock had previously closed at $4.93.

A number of brokerages have weighed in on TBRA. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Wednesday, May 4th. Zacks Investment Research upgraded shares of Tobira Therapeutics from a “hold” rating to a “strong-buy” rating and set a $9.25 price objective for the company in a research report on Thursday, May 5th. Leerink Swann reiterated a “buy” rating and issued a $18.00 price objective on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Finally, Cantor Fitzgerald began coverage on shares of Tobira Therapeutics in a research report on Wednesday, July 6th. They issued a “buy” rating and a $27.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Tobira Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.75.

The firm has a 50-day moving average of $6.02 and a 200-day moving average of $8.21. The company’s market capitalization is $92.41 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The company had revenue of $1.06 million for the quarter. Analysts forecast that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.

In related news, major shareholder A/S Novo sold 66,814 shares of Tobira Therapeutics stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $13.04, for a total transaction of $871,254.56. Following the sale, the insider now directly owns 2,073,022 shares in the company, valued at approximately $27,032,206.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.